Monday, 20 May 2019

You are here

Improving Cardiovascular Trends in Rheumatoid Arthritis

 Myasoedova and colleagues from the Mayo Clinic have reported their new data that demonstrates improving cardiovascular (CV) mortality rates in current RA patients treated with modern drugs.

They studied 813 RA patients (mean age 55.9 years; 68% female). In patients with incident RA during the 2000–2007 period, the 10-year CV mortality was 2.8% (95% CI: 0.4%, 5.2%) and coronary heart disease (CHD) mortality was 1.2% (1.0, 1.4%). These numbers demonstrate significant improvement when compared to patients diagnosed in 1990–1999. Lower rates of CV outcomes included the overall CV death rate (HR=0.43; 95% CI: 0.19, 0.94; p=0.035); and CHD death (HR 0.21; 95% CI: 0.05, 0.95).

Importantly, the lowering of RA death rates now show them to not be different than the non-RA cohort (general population). 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Opioids, SSRIs and Steroids Increase Fracture Risk in RA

Analysis of a large US observational rheumatoid arthritis (RA) patients finds that opioids, SSRIs and glucocorticoids were associated with increased risk of fracture in RA, whereas statins and TNFi had a decreased vertebral fracture risk.

Denosumab Protects Against RA Erosions

Combining denosumab (Prolia) with a conventional disease-modifying antirheumatic drug (DMARD) such as methotrexate showed promise for slowing radiographic damage in rheumatoid arthritis (RA), a manufacturer-sponsored phase III trial called DESIRABLE found.

New ACR/AF Guidelines on JIA Polyarthritis and Uveitis

The American College of Rheumatology (ACR) and the Arthritis Foundation (AF) have released two guidelines on management of juvenile idiopathic arthritis (JIA). The first addresses the treatement of non-systemic polyarthritis, sacroilitis and enthesitis; and the second focuses on JIA associated uveitis - screening, monitoring and treatment.

Shorter Treatment Succeeds in Septic Arthritis

Two weeks of antibiotic therapy was as effective as 4 weeks for septic arthritis, a prospective single-center study found.

Among 77 patients randomized to a 4-week course of therapy following surgical drainage for native joint bacterial arthritis, the rate of complete microbiological remission after at least 2 months of follow-up was 97%, according to Ilker Uçkay, MD, of Uniklinik Balgrist in Zurich, Switzerland, and colleagues.

Targeting GM-CSF Works in Rheumatoid Arthritis

Namilumab, a monoclonal antibody that targets the granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand, showed promise as a treatment for rheumatoid arthritis (RA) in a phase II study.